Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-22
2008-04-22
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212030, C514S218000, C540S488000, C540S491000, C540S531000
Reexamination Certificate
active
07361648
ABSTRACT:
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I:wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.
REFERENCES:
patent: 3054794 (1962-09-01), Shapiro et al.
patent: 3354178 (1967-11-01), Dickinson
patent: 4038407 (1977-07-01), Eberlein et al.
patent: 4065471 (1977-12-01), Dickinson
patent: 4087541 (1978-05-01), Eberlein et al.
patent: 4490369 (1984-12-01), Reiffen et al.
patent: 4729994 (1988-03-01), Carson
patent: 5047417 (1991-09-01), Minami et al.
patent: 5177089 (1993-01-01), Minami et al.
patent: 5382595 (1995-01-01), Minami et al.
patent: 5607953 (1997-03-01), Minami et al.
patent: 5693630 (1997-12-01), Bengtsson et al.
patent: 5998452 (1999-12-01), Ohi et al.
patent: 6667301 (2003-12-01), Dvorak et al.
patent: 0259793 (1988-03-01), None
patent: 2302733 (1976-10-01), None
patent: WO 99/43657 (1999-09-01), None
Silverman, Chapter 8: Prodrugs and Drug Delivery Systems, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400, 1992.
Bundgaard, Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities, Design of Prodrugs, p. 1, 1985.
Singh et al., CAPLUS Abstract 86:29756, 1977.
Reiffen, M., et al., “Specific Bradycardic Agents. 1. Chemistry, Pharamcology, and Structure-Activity Relationships of Substituted Benzazepinones, A New Class of Compounds Exerting Antiischemic Properties,” J. Med. Chem. (1990), vol. 33, No. 5, pp. 1496-1504.
Singh, et al., “Studies in Potential Filaricides: Part VII—Synthesis of I-Ethyl-3-(2-dialkylaminoethyl)-& 1,3,-Diethyl-4-dialkylaminoethyl-hexahydropyrimidin-2-ones,”Indian Journal of Chemistry, (1976), pp. 528-531, vol. 14.
Glozman, et al, “Synthesis and cardiovavscular properties of 1-dialkylaminoalkyl-4-arylpyrrolidones-2”,Khim.-Farm.Zh, (1996), pp. 11-14, 30(4), Russia.
Ehlert, et al., “Subtypes of the Muscarinic Receptor in Smooth Muscle”, (Minireview),Life Sciences, (1997), pp. 1729-1740, vol. 61.
Hedge, et al., “Muscarinic Receptor Subtypes Modulating Smooth Muscle Contractility in the Urinary Bladder”,Life Sciences, (1999),pp. 419-428, vol. 64.
Eglen, et al., “Muscarinic acetylcholine receptor subtypes in smooth muscle”,Trends. Pharmacol. Sci., (1994), pp. 114-119, vol. 15.
Eglen, et al, “Muscarinic receptor subtypes and smooth muscule function”,Pharmacol. Rev., (1996), pp. 531-565, V. 48, No. 4.
Nilvebrant, et al., “ Tolterodine—A new Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data”,Life Sciences, (1997), pp. 1129-1136, vol. 60.
Alabaster, “Discovery & Development of Selective M3Antagonists for Clinical Use”,Life Sciences, (1997), pp. 1053-1060, vol. 60, Nos. 13/14.
Osayu, et al, “Urinary Bladder-selective Action of the New Antimuscarinic Compound Vamicamide”,Drug Res., (1994), pp. 1242-1249, vol. 44(II) No. 11.
Homma, et al,—Abstract, “Randomized Double-Blind Study to Compare Clinical Efficacy of Temiverine and Propiverine for Unstable Bladder and Detrusor Hyperreflexia”,Neurology and Urodynamics, (1997), pp. 345-346, vol. 16.
Eglen and Hegde,—Chapter 4, “Selective modulation of muscarinic receptor subtypes: therapeutic potential”,Emerging Drugs, (1998), pp. 67-79, vol. 3, Ashley Publications Ltd.
Eglen, et al, “Muscarinic receptor ligands and their therapeutic potential”,Curr. Opin. Chem. Biol., (1999), pp. 426-432 , vol. 3.
Caulfield, et al, “International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors”,Pharmacological Reviews, (1998), pp. 279-290, vol. 50(2).
Reiffen, et al., “Specific Bradycardic Agents. 1. Chemistry, Pharmacology, and Structure-Activity Relationships of Substituted Benzazepinones, a New Class of Compounds Exerting Antiischemic Properties”,J. Med. Chem, 1988, pp. 55-72, vol. 36.
Takeda, “Effects of the Bradycardic Agents, Alinidine and Falipamil on Atrio-ventricular Conduction”Shinshu Medical Journal, 1988, pp. 55-72, vol. 36, No. 1.
Dvorak Charles Alois
Fisher Lawrence Emerson
Green Keena Lynn
Harris, III Ralph New
Maag Hans
Green Grant D.
Rao Deepak
Roche Palo Alto LLC
LandOfFree
Heterocyclylakylamines as muscarinic receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclylakylamines as muscarinic receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclylakylamines as muscarinic receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2772797